Literature DB >> 34111428

The Role of R-Ras Proteins in Normal and Pathologic Migration and Morphologic Change.

Shannon M Weber1, Steven L Carroll2.   

Abstract

The contributions that the R-Ras subfamily [R-Ras, R-Ras2/teratocarcinoma 21 (TC21), and M-Ras] of small GTP-binding proteins make to normal and aberrant cellular functions have historically been poorly understood. However, this has begun to change with the realization that all three R-Ras subfamily members are occasionally mutated in Noonan syndrome (NS), a RASopathy characterized by the development of hematopoietic neoplasms and abnormalities affecting the immune, cardiovascular, and nervous systems. Consistent with the abnormalities seen in NS, a host of new studies have implicated R-Ras proteins in physiological and pathologic changes in cellular morphology, adhesion, and migration in the cardiovascular, immune, and nervous systems. These changes include regulating the migration and homing of mature and immature immune cells, vascular stabilization, clotting, and axonal and dendritic outgrowth during nervous system development. Dysregulated R-Ras signaling has also been linked to the pathogenesis of cardiovascular disease, intellectual disabilities, and human cancers. This review discusses the structure and regulation of R-Ras proteins and our current understanding of the signaling pathways that they regulate. It explores the phenotype of NS patients and their implications for the R-Ras subfamily functions. Next, it covers recent discoveries regarding physiological and pathologic R-Ras functions in key organ systems. Finally, it discusses how R-Ras signaling is dysregulated in cancers and mechanisms by which this may promote neoplasia.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34111428      PMCID: PMC8420862          DOI: 10.1016/j.ajpath.2021.05.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  99 in total

1.  An Eph receptor regulates integrin activity through R-Ras.

Authors:  J X Zou; B Wang; M S Kalo; A H Zisch; E B Pasquale; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  The small GTP-binding protein R-Ras can influence integrin activation by antagonizing a Ras/Raf-initiated integrin suppression pathway.

Authors:  T Sethi; M H Ginsberg; J Downward; P E Hughes
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

3.  Molecular dissection of the semaphorin 4D receptor plexin-B1-stimulated R-Ras GTPase-activating protein activity and neurite remodeling in hippocampal neurons.

Authors:  Izumi Oinuma; Hironori Katoh; Manabu Negishi
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

4.  Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells.

Authors:  X Guo; L Stratton; J W Schrader
Journal:  Oncogene       Date:  2006-02-27       Impact factor: 9.867

5.  Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway.

Authors:  P E Hughes; M W Renshaw; M Pfaff; J Forsyth; V M Keivens; M A Schwartz; M H Ginsberg
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

6.  Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21.

Authors:  M Rosário; H F Paterson; C J Marshall
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

7.  Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.

Authors:  Marialetizia Motta; Miray Fidan; Emanuele Bellacchio; Francesca Pantaleoni; Konstantin Schneider-Heieck; Simona Coppola; Guntram Borck; Leonardo Salviati; Martin Zenker; Ion C Cirstea; Marco Tartaglia
Journal:  Hum Mol Genet       Date:  2019-03-15       Impact factor: 6.150

8.  High Endothelial Venules Accelerate Naive T Cell Recruitment by Tumor Necrosis Factor-Mediated R-Ras Upregulation.

Authors:  Junko Sawada; Carole Y Perrot; Linyuan Chen; Ashley E Fournier-Goss; Jeremiah Oyer; Alicja Copik; Masanobu Komatsu
Journal:  Am J Pathol       Date:  2020-11-04       Impact factor: 4.307

9.  Loss of the integrin-activating transmembrane protein Fam38A (Piezo1) promotes a switch to a reduced integrin-dependent mode of cell migration.

Authors:  Brian J McHugh; Amanda Murdoch; Christopher Haslett; Tariq Sethi
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

10.  Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo.

Authors:  K T Barker; M R Crompton
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more
  4 in total

Review 1.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

2.  R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.

Authors:  Shannon M Weber; Nicole M Brossier; Amanda Prechtl; Stephen Barnes; Landon S Wilson; Stephanie N Brosius; Jody Fromm Longo; Steven L Carroll
Journal:  Cell Commun Signal       Date:  2021-09-16       Impact factor: 7.525

Review 3.  Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach.

Authors:  Caio Bezerra Machado; Leidivan Sousa da Cunha; Jersey Heitor da Silva Maués; Flávia Melo Cunha de Pinho Pessoa; Marcelo Braga de Oliveira; Rodrigo Monteiro Ribeiro; Germison Silva Lopes; Manoel Odorico de Moraes Filho; Maria Elisabete Amaral de Moraes; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Int J Mol Sci       Date:  2022-05-14       Impact factor: 6.208

4.  How can same-gene mutations promote both cancer and developmental disorders?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Sci Adv       Date:  2022-01-14       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.